- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00690625
Topical Application of MyoRx (Omega 3 Fatty Acids Containing) Cream
Topical Application of MyoRx (Omega 3 Fatty Acids Containing) Cream; Randomized Double Blind Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The prevalence of clinically significant temporomandibular disorder (TMD)-related jaw pain has been estimated to be between 3% and 5%. Temporomandibular disorders (TMDs) are a group of conditions characterized by pain or dysfunction in the temporomandibular joint (TMJ), the articular disc and/or the muscles of mastication. TMD is typically classified into three major diagnostic categories, using RDC-TMD classification criteria these would include Myofacial pain (with or without limitation), Disc Displacements (with and without reduction, including with a limited opening,) and Arthralgia, Arthritis and Arthrosis. These pain problems are about twice as common in women as in men in the general population and even four times more common in women in patient populations. A wide range of treatment modalities have been used for the management of myofacial pain. Physical treatments include ultrasound therapy, appliance therapy, intramuscular and nerve root stimulation, anesthetic injection, botulinum toxin injection and dry needling of trigger points, physical therapy, acupuncture and spray and stretch. The major goal of these treatments is to relieve pain and tightness of the involved muscles. Omega-3 fatty acids or fish oil are a family of polyunsaturated fatty acids. Omega-3 fatty acids are powerful anti-inflammatories and lower proinflammatory cytokines. However to obtain any discernible beneficial effects, large doses of Omega-3 fatty acids are required. Thus, topically applied alternatives prove beneficial over systemic routes. Studies show the anti-inflammatory properties of the Omega-3 fatty acids.
This study is designed to evaluate the effectiveness of topical application of omega-3 fatty acids (6% by volume) containing cream on persons with a TMD disorder, specifically with a diagnosis of Myofacial Pain. Omega-3 fatty acids have minimal side effects when applied topically. If Omega-3 fatty acids used in this study are shown to reduce myofacial pain then this formulation could potentially be used for treatment of TMD patents with myofacial pain in the future. Omega-3 fatty acids are natural ingredients with almost no side effects. Topical application can lead to fewer side effects than systemic medications. In addition, there is no substantial morbidity & mortality associated with topical application of Omega-3 fatty acids. It is hypothesized that subjects receiving topical application of omega-3 fatty acids will demonstrate reduced subjective masseter muscle pain in comparison to subjects receiving placebo cream. This is a pilot study to assess the topical application of Omega-3 fatty acids on muscle pain in the muscles of mastication.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Washington
-
Seattle, Washington, United States, 98195
- University of Washington, Medical center, Department of Oral Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects will be recruited who are ages 18 to 70 with a current diagnosis of myofacial pain (using RDC-TMD criteria) including pain on palpation of the masseter muscle. Subjects will be recruited from the Oral Medicine Clinic, School of Dentistry. Because this is a small pilot study, and there will not be sufficient sample size/power, only female subjects will be recruited, as temporomandibular disorder is more prevalent in women than men. Additional inclusion criteria include a "Characteristic Pain Intensity" (CPI) self reported score of three or more. This will be recorded on "Baseline Questionnaire".
Exclusion Criteria:
Study exclusion criteria:
- Males
- History of the trauma in last six months
- Other chronic pain conditions such as physician diagnosis of fibromyalgia, rheumatoid arthritis, etc
- Diagnosis of the disc displacement without reduction with limited opening of TMJ
- Age (less than 18 and more than 70)
- Evidence of complicating psychological or physical conditions which would prevent the subject from understanding/ participating in the study protocol
- Temporomandibular joint surgery on the affected side
- Allergy to any of the ingredients in the placebo and the active cream.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A
MyoRx cream
|
1/2 teaspoon 3 times per day for 30 days.
|
Placebo Comparator: B
Placebo cream, same composition as experimental cream, without Omega 3 fatty acid
|
Placebo cream, no Omega 3 fatty acid
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary outcome measure is the score on the Characteristic Pain Intensity (CPI) scale is 0-10, ordinal.
Time Frame: one month
|
one month
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Secondary outcome measure is satisfaction with the cream, Pain medicine use,
Time Frame: One month
|
One month
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ashwini V Khante, DDS, University of Washington
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 07-9505-B 01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myofacial Pain
-
Cairo UniversityEnrolling by invitationBotulinum Toxin | Myofacial Pain SyndromeEgypt
-
Mashhad University of Medical SciencesUnknownMyofacial Pain SyndromeIran, Islamic Republic of
-
Fayoum UniversityEnrolling by invitation
-
Istanbul Medipol University HospitalCompleted
-
Istanbul UniversityCompletedBack Pain | Pain, MyofacialTurkey
-
Fayoum UniversityEnrolling by invitation
-
Riphah International UniversityCompletedDry Needling and Maitland Joint Mobilization Techniques in Patients With Myofacial Chronic Neck PainNeck Pain | Myofacial PainPakistan
-
George Washington UniversityRecruitingCervical Fusion | Pain, Back | Pain, Neck | Myofacial PainUnited States
-
Taif UniversityNot yet recruiting
-
Universidad de ZaragozaMinistry of Health, Kuwait; Universidad San JorgeCompletedPlantar Fascitis | Myofacial Pain Syndromes | Trigger Point Pain, MyofascialKuwait
Clinical Trials on MyoRx Cream (6% Omega 3 Fatty Acid)
-
Haukeland University HospitalUniversity of Oslo; University of BergenCompletedCardiovascular Disease
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedBreast Neoplasms | ArthralgiaUnited States
-
Pennington Biomedical Research CenterCompleted
-
Retina Foundation of the SouthwestDSM Nutritional Products, Inc.CompletedInfant DevelopmentUnited States
-
University of Sao PauloUnknownAtherosclerosis | Morbid Obesity | Systemic InflammationBrazil
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...Recruiting
-
Cedars-Sinai Medical CenterNational Institute of Mental Health (NIMH); Massachusetts General HospitalCompleted
-
University of California, San FranciscoAutism SpeaksCompleted
-
Laval UniversityUniversity of Guelph; Advance Foods and Materials Network; Institut des Nutraceutiques... and other collaboratorsCompletedInsulin Resistance | Type 2 DiabetesCanada
-
Hugo W. Moser Research Institute at Kennedy Krieger...University of California, San FranciscoCompletedAutism Spectrum Disorders | HyperactivityUnited States